Drug intelligence / Profile preview

SBX-1968

Development stage: Preclinical
Lead developer: Stramsen Biotech
Modality: Small Molecules

Overview

SBX-1968 is a plant-based drug candidate being developed by Stramsen Biotech for the treatment of prostate cancer, specifically targeting the inhibition of tumor cell proliferation and metastasis. Derived from a proprietary database of over 8,000 medicinal plants, SBX-1968 is one of the lead candidates in the company's pipeline. Stramsen Biotech has indicated that it is working toward FDA approval for the drug, and while some of its candidates are in early-stage clinical trials, the specific clinical phase and molecular mechanism of action for SBX-1968 have not been publicly disclosed.

Beyond the preview

Go deeper on SBX-1968.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBX-1968.

Explore the full profile